S
Stemson Therapeutics
Envisions a world where anyone battling the emotional trauma or social stigma of hair loss has an opportunity to truly cure their condition and safely restore their natural hair
About Stemson Therapeutics
Stemson Therapeutics is pioneering a groundbreaking approach to combat hair loss through advanced cell therapy technology. The company focuses on developing treatments that regenerate new hair follicles, a solution that has eluded traditional hair loss treatments. Stemson's primary clients are individuals suffering from hair loss, clinically known as Alopecia, which affects approximately 20% of the global population and 80 million Americans. The company operates in the biotechnology and healthcare market, specifically targeting the hair restoration segment. Stemson's business model revolves around research, development, and commercialization of its proprietary hair regeneration cell therapy products. Revenue is generated through the sale of these therapeutic products and potentially through partnerships and licensing agreements, such as their recent collaboration with Aderans Company, the parent company of Bosley and HAIRCLUB. This agreement grants Stemson exclusive global rights to further develop and market their innovative hair regeneration solutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- San Diego, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 67.4/100
- Industry
- Health, Wellness Beauty
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jul 2021 | $15M | $60M | Genoa Ventures · Abbvie Biotech Ventures · DCVC | — |
| SEED✓Equity / VC | Sep 2020 | $7.5M | $30M | Allergan Aesthetics · Fortunis Capital | — |
Growth signals
Latest recorded traffic for Stemson Therapeutics is 29K monthly website visits, down 19.4% over the last three months. Stemson Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Fortunis Capital- AAAllergan Aesthetics
Series A3 investors entered at this stage
DCVC
Genoa Ventures
Abbvie Biotech Ventures
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stemson Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stemson Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.